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Background
One of the major challenges in long term psychophar-
macological management of schizophrenia is develop-
ment of side effects, most notably tardive dyskinesia.
T h ep r o b l e mo ft a r d i v ed y s k i n e s i a( T D )w a sm o r ep r e -
valent with the use of first - generation anti psychotic
medications; the second generation drugs are believed
to have a lesser propensity to cause such movement dis-
order. However, once TD develops the treatment
options are rather limited, with the possible exception
of Clozapine - usually modestly effective in about half of
the patients. Thus there exists a need for searching
alternative therapeutic methods for tackling this vexing
problem.
Aim
The aim was to find out if use of quetiapine is asso-
ciated with a decrease in tardive dyskinesia, in young
patients of schizophrenia who developed TD on their
first anti psychotic medication.
Materials and methods
This was an open label observation study involving six
male patients diagnosed as suffering from acute schizo-
phrenia for which they had been prescribed anti psycho-
tic medications, namely haloperidol and Risperidone.
The patients went on to develop tardive dyskinesias.
The dyskinetic movements were predominantly invol-
ving facial and oral areas. The dyskinetic movements
were rated with Abnormal Involuntary Movements
Scale. Attempts to decrease or withdraw the drugs
resulted in re-emergence of symptoms. A trial of quetia-
pine was carried out with a cross over and taper method
of 2-3 weeks. The AIMS ratings were carried out at 0,
4 and 8 week intervals. A reduction in the scores on
AIMS was observed.
Results
It was observed that young male patients (< 30 yrs.) who
had received either haloperidol (5- 12.5 mgs./day) or Ris-
peridone (4- 8 mgs./day) in oral formulations as their
first anti psychotic medication. They had these drugs for
4 - 9 month duration. All of them also had received oral
trihexyphenidyl (2-6 mgs./day) concomitantly, but still
developed involuntary movements. Their personal, family
and medical history and physical examination, including
neurological examination, were free of any neurological
or movement disorder. They were not receiving any
other concomitant medications. After cross-taper, quetia-
pine was used at 300- 600 mgs./day dose. AIMS ratings at
4 and 8 weeks after start of quetiapine therapy revealed a
decrease in tongue, lips and perioral movements.
Detailed ratings will be discussed at presentation.
Conclusions
Although Clozapine has been found to result in decrease
of TD movements; its use is problematic due to
side-effects and regular blood monitoring, which is very
difficult in developing countries. Quetiapine, associated
with least propensity for causing EPSEs, appears to be
promising for decreasing TD. This case report supports
the limited evidence base in support of the use of
quetiapine for managing tardive dyskinesia, especially in
a younger population who themselves have somewhat
lesser propensity to develop TD.
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